Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 392
5
Diseases
27
Unique genes
0.102
Avg. similarity score
Behavior disorders
Most-connected disease (3 links)
Disease
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Behavior disorders
Asperger syndrome
Dysthymic disorder
Fatigue syndrome
Early-onset obesity-hyperphagia-severe developmental delay syndrome
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Behavior disorders | 3 | 3 | 1 |
| Asperger syndrome | 2 | 2 | 9 |
| Dysthymic disorder | 2 | 2 | 7 |
| Fatigue syndrome | 2 | 2 | 14 |
| Early-onset obesity-hyperphagia-severe developmental delay syndrome | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| SLC6A4 | 4 / 5 | Asperger syndrome, Behavior disorders, Dysthymic disorder, Fatigue syndrome |
| DISC1 | 2 / 5 | Asperger syndrome, Fatigue syndrome |
| NTRK2 | 2 / 5 | Dysthymic disorder, Early-onset obesity-hyperphagia-severe developmental delay syndrome |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Defective MAOA causes Brunner syndrome (BRUNS) | Reactome | 1 / 1 | 445× | 2.25e-3 | 2.48e-2 ✓ sig. |
| Serotonin clearance from the synaptic cleft | Reactome | 1 / 1 | 445× | 2.25e-3 | 2.48e-2 ✓ sig. |
| Enzymatic degradation of Dopamine by monoamine oxidase | Reactome | 1 / 2 | 222× | 4.49e-3 | 4.08e-2 ✓ sig. |
| Metabolism of serotonin | Reactome | 1 / 2 | 222× | 4.49e-3 | 4.08e-2 ✓ sig. |
| Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB | Reactome | 1 / 2 | 222× | 4.49e-3 | 4.08e-2 ✓ sig. |
| Graft-versus-host disease | KEGG | 2 / 45 | 19.8× | 4.54e-3 | 4.11e-2 ✓ sig. |
| Enzymatic degradation of dopamine by COMT | Reactome | 1 / 3 | 148× | 6.73e-3 | 5.32e-2 |
| Axon guidance | KEGG | 3 / 183 | 7.3× | 7.78e-3 | 5.86e-2 |
| Alcoholism | KEGG | 3 / 188 | 7.1× | 8.38e-3 | 6.15e-2 |
| L1CAM interactions | Reactome | 1 / 4 | 111× | 8.96e-3 | 6.42e-2 |
| Activated NTRK2 signals through PLCG1 | Reactome | 1 / 4 | 111× | 8.96e-3 | 6.42e-2 |
| NTRK2 activates RAC1 | Reactome | 1 / 5 | 89.0× | 1.12e-2 | 7.34e-2 |
| Activated NTRK2 signals through FRS2 and FRS3 | Reactome | 1 / 6 | 74.1× | 1.34e-2 | 8.14e-2 |
| Antigen processing and presentation | KEGG | 2 / 81 | 11.0× | 1.41e-2 | 8.41e-2 |
| Aspartate and asparagine metabolism | Reactome | 1 / 12 | 37.1× | 2.67e-2 | 1.21e-1 |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| positive regulation of cAMP/PKA signal transduction | GO:0141163 | 2 / 16 | 86.5× | 2.38e-4 | 5.71e-3 ✓ sig. |
| positive regulation of cell-matrix adhesion | GO:0001954 | 2 / 27 | 51.3× | 6.90e-4 | 1.19e-2 ✓ sig. |
| regulation of postsynapse organization | GO:0099175 | 2 / 34 | 40.7× | 1.10e-3 | 1.60e-2 ✓ sig. |
| positive regulation of ion transmembrane transporter activity | GO:0032414 | 1 / 1 | 692× | 1.44e-3 | 1.87e-2 ✓ sig. |
| positive regulation of digestive system process | GO:0060456 | 1 / 1 | 692× | 1.44e-3 | 1.87e-2 ✓ sig. |
| diadenosine triphosphate catabolic process | GO:0015964 | 1 / 1 | 692× | 1.44e-3 | 1.87e-2 ✓ sig. |
| positive regulation of serotonin secretion | GO:0014064 | 1 / 1 | 692× | 1.44e-3 | 1.87e-2 ✓ sig. |
| regulation of thalamus size | GO:0090067 | 1 / 1 | 692× | 1.44e-3 | 1.87e-2 ✓ sig. |
| tricuspid valve development | GO:0003175 | 1 / 1 | 692× | 1.44e-3 | 1.87e-2 ✓ sig. |
| embryonic heart tube elongation | GO:0036306 | 1 / 1 | 692× | 1.44e-3 | 1.87e-2 ✓ sig. |
| lateral mesoderm formation | GO:0048370 | 1 / 1 | 692× | 1.44e-3 | 1.87e-2 ✓ sig. |
| epinephrine secretion | GO:0048242 | 1 / 1 | 692× | 1.44e-3 | 1.87e-2 ✓ sig. |
| negative regulation of nervous system development | GO:0051961 | 1 / 1 | 692× | 1.44e-3 | 1.87e-2 ✓ sig. |
| positive regulation of BMP signaling pathway | GO:0030513 | 2 / 40 | 34.6× | 1.52e-3 | 1.93e-2 ✓ sig. |
| regulation of serotonin secretion | GO:0014062 | 1 / 2 | 346× | 2.89e-3 | 2.76e-2 ✓ sig. |
Pairs within this cluster, by significance
| Disease A ⇵ | Disease B ⇵ | Similarity score ⇵ | Shared genes ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Asperger syndrome | Fatigue syndrome | 0.091 | 2 | 2.75e-5 | 1.35e-4 ✓ sig. |
| Behavior disorders | Dysthymic disorder | 0.125 | 1 | 4.55e-4 | 9.55e-4 ✓ sig. |
| Dysthymic disorder | Early-onset obesity-hyperphagia-severe developmental delay syndrome | 0.125 | 1 | 4.55e-4 | 9.55e-4 ✓ sig. |
| Asperger syndrome | Behavior disorders | 0.100 | 1 | 5.84e-4 | 1.14e-3 ✓ sig. |
| Behavior disorders | Fatigue syndrome | 0.067 | 1 | 9.09e-4 | 1.56e-3 ✓ sig. |